Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 12;71(6):1410-1412.
doi: 10.1093/cid/ciaa453.

Weak Induction of Interferon Expression by Severe Acute Respiratory Syndrome Coronavirus 2 Supports Clinical Trials of Interferon-λ to Treat Early Coronavirus Disease 2019

Thomas R O'Brien  1 , David L Thomas  2 , Sarah S Jackson  1 , Ludmila Prokunina-Olsson  3 , Raymond P Donnelly  4 , Rune Hartmann  5
Affiliations

Weak Induction of Interferon Expression by Severe Acute Respiratory Syndrome Coronavirus 2 Supports Clinical Trials of Interferon-λ to Treat Early Coronavirus Disease 2019

Thomas R O'Brien et al. Clin Infect Dis. .
No abstract available

Keywords: MERS-CoV; SARS-CoV; innate immunity; severe acute respiratory syndrome; virology.

PubMed Disclaimer

Comment in

  • doi: 10.1093/cid/ciaa410

References

    1. Lu R, Zhao X, Li J, et al. . Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020; 395:565–74. - PMC - PubMed
    1. de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol 2016; 14:523–34. - PMC - PubMed
    1. Chu H, Chan JF-W, Wang Y, et al. . Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19 [manuscript published online ahead of print]. Clin Infect Dis 2020. doi:10.1093/cid/ciaa410. - PMC - PubMed
    1. Kotenko SV, Gallagher G, Baurin VV, et al. . IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003; 4:69–77. - PubMed
    1. Sheppard P, Kindsvogel W, Xu W, et al. . IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003; 4:63–8. - PubMed

Publication types